LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.

Ueyama, Azumi / Nogami, Wataru / Nashiki, Kunitaka / Haruna, Miya / Miwa, Hiroto / Hagiwara, Masaki / Nagira, Morio / Wada, Hisashi / Nagira, Yoji

Journal of immunology (Baltimore, Md. : 1950)

2023 Volume 211, Issue 4, Page(s) 673–682

Abstract: Regulatory T cells (Tregs) contribute to the formation of a tumor-immunosuppressive microenvironment. CCR8 is reportedly selectively expressed in tumor Tregs, and an anti-CCR8 Ab can exert potent antitumor effects by eliminating intratumor Tregs in ... ...

Abstract	Regulatory T cells (Tregs) contribute to the formation of a tumor-immunosuppressive microenvironment. CCR8 is reportedly selectively expressed in tumor Tregs, and an anti-CCR8 Ab can exert potent antitumor effects by eliminating intratumor Tregs in murine tumor models. In this study, we analyzed changes to intratumor immunity after anti-CCR8 Ab administration, especially in CD8+ T cells, which are involved in cancer cell killing, using the CT26 colorectal carcinoma mouse model. Immunophenotyping of tumor-infiltrating cells by mass cytometry after Ab administration on day 5 of tumor inoculation revealed that CD8+ T cell subsets were dramatically altered in the CCR8 Ab-treated group, with an increase in naive cells and nonexhausted effector cells and a decrease in exhausted cells with high expression levels of TOX. These results were corroborated with flow cytometry analysis. Delayed administration of the anti-CCR8 Ab on day 9 or 12, when the amount of CCR8+ Tregs and CD8+ T cell exhaustion were more progressed, also resulted in a decrease in exhausted CD8+ T cells, leading to tumor regression. Finally, we confirmed that high CCR8+ Treg infiltration was associated with high TOX expression in CD8+ T cells in human cancer patients. In conclusion, administration of an anti-CCR8 Ab can dramatically alter the activation and exhaustion state of intratumor CD8+ T cells, resulting in strong antitumor effects. In cancer patients with an advanced tumor-immunosuppressive environment, CD8+ T cell exhaustion has progressed along with CCR8+ Treg induction. Therefore, targeted depletion of CCR8+ Tregs is expected to be effective in these patients.
MeSH term(s)	Humans ; Animals ; Mice ; T-Lymphocytes, Regulatory ; CD8-Positive T-Lymphocytes ; Immunotherapy/methods ; Neoplasms/pathology ; Tumor Microenvironment
Language	English
Publishing date	2023-06-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	3056-9
ISSN	1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
ISSN (online)	1550-6606
ISSN	0022-1767 ; 1048-3233 ; 1047-7381
DOI	10.4049/jimmunol.2300067
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.37: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 28: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.

Nagira, Yoji / Nagira, Morio / Nagai, Ryohei / Nogami, Wataru / Hirata, Michinari / Ueyama, Azumi / Yoshida, Tetsuya / Yoshikawa, Mai / Shinonome, Satomi / Yoshida, Hiroshi / Haruna, Miya / Miwa, Hiroto / Chatani, Natsumi / Ohkura, Naganari / Wada, Hisashi / Tanaka, Hidekazu

Molecular cancer therapeutics

2023 Volume 22, Issue 9, Page(s) 1063–1072

Abstract: Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating ... ...

Abstract	Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti-PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.
MeSH term(s)	Humans ; Receptors, Chemokine/metabolism ; T-Lymphocytes, Regulatory ; Neoplasms/drug therapy ; Immunity ; Lymphocytes, Tumor-Infiltrating
Chemical Substances	Receptors, Chemokine
Language	English
Publishing date	2023-07-05
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2063563-1
ISSN	1538-8514 ; 1535-7163
ISSN (online)	1538-8514
ISSN	1535-7163
DOI	10.1158/1535-7163.MCT-22-0570
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5750: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: T cell immunity in interstitial lung disease with non-small cell lung cancer patients.

Isono, Tomomi / Iwahori, Kota / Yanagawa, Masahiro / Yamamoto, Yoko / Tone, Mari / Haruna, Miya / Hirata, Michinari / Fukui, Eriko / Kimura, Toru / Kanou, Takashi / Ose, Naoko / Funaki, Soichiro / Takeda, Yoshito / Morii, Eiichi / Kumanogoh, Atsushi / Shintani, Yasushi / Wada, Hisashi

Lung cancer (Amsterdam, Netherlands)

2023 Volume 182, Page(s) 107278

Abstract: Objectives: Limited treatment options are available for non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD). The rationale for immunotherapy and its adverse events for NSCLC with ILD remains unclear. In this study, we ... ...

Abstract	Objectives: Limited treatment options are available for non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD). The rationale for immunotherapy and its adverse events for NSCLC with ILD remains unclear. In this study, we examined T cell profiles and functions in the lung tissues of NSCLC patients with or without ILD to provide evidence for the potential mechanism of immune checkpoint inhibitor (ICI)-related pneumonitis in NSCLC patients with ILD. Material and methods: We investigated T cell immunity in the lung tissues of NSCLC patients with ILD to support the application of immunotherapy for these patients. We analyzed T cell profiles and functions in surgically resected lung tissues from NSCLC patients with and without ILD. The T cell profiles of infiltrating cells in lung tissues were analyzed by flow cytometry. T cell functions were measured based on cytokine production by T cells stimulated with phorbol 12-myristate 13-acetate and ionomycin. Results: The percentages of CD4 Conclusion: In NSCLC patients with ILD stable for surgery, T cells were active participants and balanced in part by Treg cells in lung tissues, suggesting the potential development of ICI-related pneumonitis in NSCLC patients with ILD.
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/therapy ; Lung Neoplasms/therapy ; CD8-Positive T-Lymphocytes ; Tumor Necrosis Factor-alpha ; Lung Diseases, Interstitial ; Pneumonia ; Retrospective Studies
Chemical Substances	Tumor Necrosis Factor-alpha
Language	English
Publishing date	2023-06-09
Publishing country	Ireland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	632771-0
ISSN	1872-8332 ; 0169-5002
ISSN (online)	1872-8332
ISSN	0169-5002
DOI	10.1016/j.lungcan.2023.107278
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2135: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 423: Show issues

Order via subito

Details ▾

Article ; Online: The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.

Haruna, Miya / Ueyama, Azumi / Yamamoto, Yoko / Hirata, Michinari / Goto, Kumiko / Yoshida, Hiroshi / Higuchi, Naoko / Yoshida, Tetsuya / Kidani, Yujiro / Nakamura, Yamami / Nagira, Morio / Kawashima, Atsunari / Iwahori, Kota / Shintani, Yasushi / Ohkura, Naganari / Wada, Hisashi

Scientific reports

2022 Volume 12, Issue 1, Page(s) 5377

Abstract: Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments. Recent studies identified selective CCR8 ... ...

Abstract	Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments. Recent studies identified selective CCR8 expression on tumor-infiltrating Tregs; CCR8+ Tregs have been indicated as a possible new target of cancer immunotherapy. Here, we investigated the features of CCR8+ Tregs in lung cancer patients. CCR8+ Tregs were highly activated and infiltration of CCR8+ Tregs in tumors was associated with poor prognosis in lung cancer patients. We also investigated their immune suppressive function, especially the influence on cytotoxic T lymphocyte cell function. The Cancer Genome Atlas analysis revealed that CD8 T cell activities were suppressed in high CCR8-expressing tumors. Additionally, depletion of CCR8+ cells enhanced CD8 T cell function in an ex vivo culture of lung tumor-infiltrating cells. Moreover, CCR8+ Tregs, but not CCR8- Tregs, induced from human PBMCs markedly suppressed CD8 T cell cytotoxicity. Finally, we demonstrated the therapeutic effect of targeting CCR8 in a murine model of lung cancer. These findings reveal the significance of CCR8+ Tregs for immunosuppression in lung cancer, especially via cytotoxic T lymphocyte cell suppression, and suggest the potential value of CCR8-targeted therapy for cancer treatment.
MeSH term(s)	Animals ; Humans ; Immune Tolerance ; Immunotherapy ; Lung Neoplasms/pathology ; Mice ; Receptors, CCR8/metabolism ; T-Lymphocytes, Cytotoxic ; T-Lymphocytes, Regulatory
Chemical Substances	CCR8 protein, human ; Ccr8 protein, mouse ; Receptors, CCR8
Language	English
Publishing date	2022-03-30
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-022-09458-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Tumor-infiltrating ICOS

Kajikawa, Hitomi / Hirata, Michinari / Haruna, Miya / Ueyama, Azumi / Hirose, Katsutoshi / Kawashima, Atsunari / Iwahori, Kota / Matsunaga, Kazuhide / Toyosawa, Satoru / Uzawa, Narikazu / Wada, Hisashi

Anticancer research

2022 Volume 42, Issue 5, Page(s) 2383–2393

Abstract: Background: Tumor immunity in the tumor microenvironment is activated in patients with feasible clinical responses to immune checkpoint inhibitors. The immunological profile of tumor-infiltrating lymphocytes (TILs) obtained from patients with oral ... ...

Abstract	Background: Tumor immunity in the tumor microenvironment is activated in patients with feasible clinical responses to immune checkpoint inhibitors. The immunological profile of tumor-infiltrating lymphocytes (TILs) obtained from patients with oral squamous cell carcinoma (OSCC) was examined in relation to their prognosis. Materials and methods: Surface antigens, including immune checkpoint molecules, on TILs from 31 patients with primary OSCC were analyzed by flow cytometry. The activation status of TILs was examined through a heatmap analysis and unsupervised clustering classified patients into groups with activated or inactivated TILs. A supervised machine-learning algorithm for single-cell analyses in relation to prognosis was run using the Cluster Identification, Characterization, and Regression (CITRUS) program. Results: None of surface antigens were related to prognosis. The CITRUS program revealed a relationship between CD45RA Conclusion: CD25
MeSH term(s)	Carcinoma, Squamous Cell ; Head and Neck Neoplasms ; Humans ; Immune Checkpoint Inhibitors ; Inducible T-Cell Co-Stimulator Protein/metabolism ; Mouth Neoplasms/pathology ; Prognosis ; Squamous Cell Carcinoma of Head and Neck ; T-Lymphocytes, Regulatory ; Tumor Microenvironment
Chemical Substances	ICOS protein, human ; Immune Checkpoint Inhibitors ; Inducible T-Cell Co-Stimulator Protein
Language	English
Publishing date	2022-04-27
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.15717
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.

Nose, Yohei / Saito, Takuro / Yamamoto, Kei / Yamashita, Kotaro / Tanaka, Koji / Yamamoto, Kazuyoshi / Makino, Tomoki / Takahashi, Tsuyoshi / Kawashima, Atsunari / Haruna, Miya / Hirata, Michinari / Ueyama, Azumi / Iwahori, Kota / Satoh, Taroh / Kurokawa, Yukinori / Eguchi, Hidetoshi / Doki, Yuichiro / Wada, Hisashi

Cancer immunology, immunotherapy : CII

2022 Volume 72, Issue 1, Page(s) 169–181

Abstract: Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell ... ...

Abstract	Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer. Methods: We collected peripheral blood samples from gastric cancer patients (n = 29) before and after treatment with nivolumab and investigated the relationship between the frequency of surface or intracellular markers among nivolumab-binding PD-1 Results: Patients with a high frequency of CD103 among PD-1 Conclusions: A high frequency of CD103 among PD-1
MeSH term(s)	Humans ; Stomach Neoplasms/pathology ; Nivolumab/therapeutic use ; Nivolumab/pharmacology ; CD8-Positive T-Lymphocytes ; Biomarkers/metabolism ; Progression-Free Survival
Chemical Substances	Nivolumab (31YO63LBSN) ; Biomarkers
Language	English
Publishing date	2022-07-01
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-022-03240-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.

Haruna, Miya / Hirata, Michinari / Iwahori, Kota / Kanazawa, Takayuki / Yamamoto, Yoko / Goto, Kumiko / Kawashima, Atsunari / Morimoto-Okazawa, Akiko / Funaki, Soichiro / Shintani, Yasushi / Kumanogoh, Atsushi / Wada, Hisashi

Biological & pharmaceutical bulletin

2020 Volume 43, Issue 3, Page(s) 399–403

Abstract: Immune checkpoint inhibitors (ICIs) exert beneficial effects in non-small cell lung cancer (NSCLC) patients. However, ICIs are only advantageous for a limited population of NSCLC patients. Therefore to enhance their effects, combination therapies with ... ...

Abstract	Immune checkpoint inhibitors (ICIs) exert beneficial effects in non-small cell lung cancer (NSCLC) patients. However, ICIs are only advantageous for a limited population of NSCLC patients. Therefore to enhance their effects, combination therapies with ICIs have been developed. To identify preferable chemotherapy to combine with ICIs against lung cancer, we examined immunological effects of docetaxel compared with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We found no difference in peripheral lymphocyte counts and ratio of their subpopulations in lung cancer patients before and after both treatments. On the other hand, plasma levels of high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, showed significant increase after docetaxel treatment. Furthermore, we investigated effects of HMGB1 on tumor-infiltrating immune cells obtained from surgically resected tumor tissue from NSCLC patients. When the tumor infiltrating cells were stimulated with HMGB1, CD11c
MeSH term(s)	A549 Cells ; Antineoplastic Agents ; CD11 Antigens/metabolism ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cell Line, Tumor ; Chemokines/metabolism ; Combined Modality Therapy ; Cytokines/metabolism ; Docetaxel/pharmacology ; Epidermal Growth Factor/antagonists & inhibitors ; ErbB Receptors/antagonists & inhibitors ; Female ; HMGB1 Protein/blood ; HMGB1 Protein/metabolism ; Humans ; Integrin alpha Chains/metabolism ; Male ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Transcriptional Activation/drug effects
Chemical Substances	Antineoplastic Agents ; CD11 Antigens ; Chemokines ; Cytokines ; HMGB1 Protein ; HMGB1 protein, human ; ITGAD protein, human ; Integrin alpha Chains ; Protein Kinase Inhibitors ; Docetaxel (15H5577CQD) ; Epidermal Growth Factor (62229-50-9) ; ErbB Receptors (EC 2.7.10.1) ; Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2020-02-28
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1150271-x
ISSN	1347-5215 ; 0918-6158
ISSN (online)	1347-5215
ISSN	0918-6158
DOI	10.1248/bpb.b19-00702
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1474: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells.

Urakawa, Shinya / Yamasaki, Makoto / Goto, Kumiko / Haruna, Miya / Hirata, Michinari / Morimoto-Okazawa, Akiko / Kawashima, Atsunari / Iwahori, Kota / Makino, Tomoki / Kurokawa, Yukinori / Yamada, Tomomi / Mori, Masaki / Doki, Yuichiro / Wada, Hisashi

Cancer immunology, immunotherapy : CII

2019 Volume 68, Issue 8, Page(s) 1341–1350

Abstract: Gastric cancer (GC) is the most common malignant tumor in digestive organs, and the prognosis of GC patients who have undergone surgery remains poor because of frequent recurrence. Therefore, the identification of new markers to predict the outcome of ... ...

Abstract	Gastric cancer (GC) is the most common malignant tumor in digestive organs, and the prognosis of GC patients who have undergone surgery remains poor because of frequent recurrence. Therefore, the identification of new markers to predict the outcome of these patients is needed. Monocyte count is a negative prognostic factor associated with inflammation. We investigated the relationship between peripheral monocytes in the peri-operative period and prognosis in GC patients. A high pre-operative monocyte count was identified as a prognostic factor in a retrospective analysis of 278 stage II and III GC patients who underwent curative gastrectomy. In contrast, an increased post-operative monocyte count compared to the pre-operative monocyte count was a marker of poor prognosis, particularly for early relapse. In a prospective analysis of 75 GC patients, a subset of the increased post-operative monocytes was similar to CD14
MeSH term(s)	Aged ; Biomarkers, Tumor ; Cell Count/methods ; Cells, Cultured ; Female ; Flow Cytometry ; Gastrectomy ; Humans ; Male ; Monocytes/pathology ; Myeloid-Derived Suppressor Cells/pathology ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Perioperative Period ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/immunology ; Stomach Neoplasms/mortality ; Survival Analysis
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2019-07-19
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-019-02366-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.

Sawada, Masaaki / Goto, Kumiko / Morimoto-Okazawa, Akiko / Haruna, Miya / Yamamoto, Kei / Yamamoto, Yoko / Nakagawa, Satoshi / Hiramatsu, Kosuke / Matsuzaki, Shinya / Kobayashi, Eiji / Kawashima, Atsunari / Hirata, Michinari / Iwahori, Kota / Kimura, Toshihiro / Ueda, Yutaka / Kimura, Tadashi / Wada, Hisashi

International immunology

2020 Volume 32, Issue 6, Page(s) 397–405

Abstract: Persistent exposure to tumor antigens results in exhausted tumor-infiltrating T cells (TILs) that express the immune checkpoint molecules, PD-1 and Tim3, and lack anti-tumor immunity. To examine the exhausted status of TILs in ovarian cancer, the ... ...

Abstract	Persistent exposure to tumor antigens results in exhausted tumor-infiltrating T cells (TILs) that express the immune checkpoint molecules, PD-1 and Tim3, and lack anti-tumor immunity. To examine the exhausted status of TILs in ovarian cancer, the potential for cytokine production, proliferation and cytotoxicity by purified PD-1+ Tim3+ CD8 TILs was assessed. The production of IFN-γ and TNF-α by PD-1+ Tim3+ CD8 TILs remained the same in an intracellular cytokine staining assay and was higher in a cytokine catch assay than that by PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. %Ki67+ was higher in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- CD8 TILs. However, patients with high PD-1+ Tim3+ CD8 TILs had a poor prognosis. The potential for cytotoxicity was then examined. %Perforin+ and %granzyme B+ were lower in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. To observe the potential for direct cytotoxicity by T cells, a target cell line expressing membrane-bound anti-CD3scFv was newly established and a cytotoxic assay targeting these cells was performed. The cytotoxicity of PD-1+ Tim3+ CD8 TILs was significantly lower than that of PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. Even though PD-1+ Tim3+ CD8 TILs in ovarian cancer showed a sustained potential for cytokine production and proliferation, cytotoxicity was markedly impaired, which may contribute to the poor prognosis of patients with ovarian cancer. Among the impaired functions of exhausted TILs, cytotoxicity may be an essential target for cancer immunotherapy.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; CD8-Positive T-Lymphocytes/immunology ; Cell Proliferation ; Female ; Hepatitis A Virus Cellular Receptor 2/deficiency ; Hepatitis A Virus Cellular Receptor 2/immunology ; Humans ; Immunotherapy ; Interferon-gamma/biosynthesis ; Interferon-gamma/immunology ; Lymphocytes, Tumor-Infiltrating/immunology ; Middle Aged ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/therapy ; Programmed Cell Death 1 Receptor/deficiency ; Programmed Cell Death 1 Receptor/immunology
Chemical Substances	HAVCR2 protein, human ; Hepatitis A Virus Cellular Receptor 2 ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Interferon-gamma (82115-62-6)
Language	English
Publishing date	2020-02-07
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1013745-2
ISSN	1460-2377 ; 0953-8178
ISSN (online)	1460-2377
ISSN	0953-8178
DOI	10.1093/intimm/dxaa010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2619: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 70: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of ICOS

Urakawa, Shinya / Yamasaki, Makoto / Makino, Tomoki / Kurokawa, Yukinori / Yamamoto, Kei / Goto, Kumiko / Haruna, Miya / Hirata, Michinari / Morimoto-Okazawa, Akiko / Kawashima, Atsunari / Iwahori, Kota / Mizushima, Tsunekazu / Sato, Eiichi / Mori, Masaki / Doki, Yuichiro / Wada, Hisashi

Cancer immunology, immunotherapy : CII

2020 Volume 70, Issue 2, Page(s) 443–452

Abstract: It remains unclear whether Helicobacter pylori (H. pylori), a major cause of gastric cancer (GC), is involved in other intestinal cancers. In our previous study, ... ...

Abstract	It remains unclear whether Helicobacter pylori (H. pylori), a major cause of gastric cancer (GC), is involved in other intestinal cancers. In our previous study, ICOS
MeSH term(s)	Colorectal Neoplasms/pathology ; Colorectal Neoplasms/virology ; Female ; Helicobacter Infections/immunology ; Helicobacter pylori/pathogenicity ; Humans ; Male ; Preoperative Care ; Prognosis ; Stomach Neoplasms/pathology ; Stomach Neoplasms/virology ; T-Lymphocytes, Regulatory/immunology
Language	English
Publishing date	2020-08-16
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-020-02696-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito